ArticleLupus2020
SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus.
Article in Lupus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- CD169 expression of CD14BMC infectious diseases · 2026Article
- Discovery of core genes for systemic lupus erythematosus via genome-wide aggregated trans-effects analysis.Genes and immunity · 2025Article
- Bioinformatic analysis and experimental verification reveal expansion of monocyte subsets with an interferon signature in systemic lupus erythematosus patients.Arthritis research & therapy · 2025Article
- Exploring CD169Vaccines · 2025Review
- Integrin β2 Plays a Significant Role in Therapeutic Angiogenesis Through Hematopoietic Stem Cell Transplantation.Life (Basel, Switzerland) · 2025Article
- Cross-disease transcriptomic meta-analysis and network pharmacology reveal key therapeutic targets in rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.Frontiers in bioinformatics · 2025Article
- Neutrophils disrupt B-1a cell homeostasis by targeting Siglec-G to exacerbate sepsis.Cellular & molecular immunology · 2024Article
- Siglec-1, an easy and contributory inflammation marker in rheumatology.Clinical & translational immunology · 2024Article
- SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity.Scientific reports · 2022Article
- SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.Journal of clinical immunology · 2022Article
- SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.RMD open · 2022Article
- [Systemic lupus erythematosus-are children small adults?]Zeitschrift fur Rheumatologie · 2022Review
- Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease.Frontiers in medicine · 2022Review
- Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer.Frontiers in immunology · 2022Article
- Analyzing the pathogenesis of systemic lupus erythematosus complicated by atherosclerosis using transcriptome data.Frontiers in immunology · 2022Article
- High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients.Pathogens (Basel, Switzerland) · 2021Article
- Validation of a Quick Flow Cytometry-Based Assay for Acute Infection Based on CD64 and CD169 Expression. New Tools for Early Diagnosis in COVID-19 Pandemic.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE).
methods27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis.
resultsIn general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (beta
conclusionsSIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.